Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11727
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVarghayee, Naghmehen
dc.contributor.authorKrezel, Michael Aen
dc.contributor.authorRezmann, Linda Adrianaen
dc.contributor.authorChow, Laurie T Cen
dc.contributor.authorFrauman, Albert Gen
dc.contributor.authorLouis, William Jen
dc.contributor.authorLouis, Simon N Sen
dc.date.accessioned2015-05-16T01:21:10Z
dc.date.available2015-05-16T01:21:10Z
dc.date.issued2013-04-04en
dc.identifier.citationJournal of the Renin-angiotensin-aldosterone System : Jraas 2013; 16(1): 79-91en
dc.identifier.govdoc23559668en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11727en
dc.description.abstractCardiac hypertrophy in myocytes is in part regulated by changes in expression of a novel Ang II type 2 receptor (AT2-receptor) interacting protein identified as ATIP.The role of the AT2-receptor in cardiac hypertrophy is controversial, with some reports indicating that AT2-receptor activation has detrimental effects on disease progression, whereas others indicate that it has a beneficial role.In an effort to unravel this paradox, we examined the expression and function of ATIP in cell-based models of cardiac hypertrophy using QPCR, immunohistochemistry, cell proliferation, morphological and transfection techniques in H9c2 cardio-myoblast and myotubules.These studies indicate that in cultured cardio-myoblast and myotubules, Ang II mediates cellular hypertrophy and proliferation solely via the AT1-receptor, the ATIP variants are abundantly expressed and that ATIP3 may play an anti-proliferative/hypertrophic role in these cells in the absence of AT2-receptor expression or activation.Previously ATIP has been shown to inhibit growth factor signalling in cancerous cells via an interaction with the AT2-receptor. This is the first report to identify that ATIP may have a similar role in other disease states characterised by excessive growth and indicates that for ATIP3, at least, an interaction with the AT2-receptor may not be necessary.en
dc.language.isoenen
dc.subject.otherATIPen
dc.subject.otherAngiotensin IIen
dc.subject.otherERK phosphorylationen
dc.subject.otherangiotensin II type 2 receptoren
dc.subject.othercardiac hypertrophyen
dc.titleFunction and expression of ATIP and its variants in cardiomyoblast cell line H9c2.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of the renin-angiotensin-aldosterone system : JRAASen
dc.identifier.affiliationClinical Pharmacology and Therapeutics Unit, Department of Medicine, University of Melbourne, Austin Health, Australiaen
dc.identifier.doi10.1177/1470320313483845en
dc.description.pages79-91en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/23559668en
dc.type.austinJournal Articleen
local.name.researcherFrauman, Albert G
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptClinical Pharmacology and Therapeutics-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

68
checked on Dec 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.